Work

Treatment of recalcitrant discoid lupus erythematosus with roflumilast 0.3% cream following suboptimal response to anifrolumab and improvement of hypopigmentation

Year: 2024

Type: article

Abstract: Discoid lupus erythematosus (DLE) is a common type of chronic cutaneous lupus erythematosus. It is an autoimmune condition that presents as erythematous, scaly plaque(s) that can progress to permanent scarring and hyper and hypopigmentation; it is typically photodistributed.1 Treatment options include aggressive ultrapotent topical steroids, topical calcineurin inhibitors, topical Janus kinase inhibitors, antimalarial agents, and other aggressive immunosuppressants.1 We present a case of recalcitrant DLE who improved with roflumilast 0.3% cream after a suboptimal response to anifrolumab infusion.

Source: JAAD Case Reports

DOI: 10.1016/j.jdcr.2024.09.016

Authors: Kareena S. Garg, Leonardo A. Tjahjono

Institutions: Georgetown University, George Washington University

Language: English

Topic: Systemic Lupus Erythematosus Research

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $750